Skip to content
Clinical Trials – home
AustriaBack to Austria

Clinical trials in Eisenstadt – page 50

861 clinical trials in Eisenstadt, Austria. Every trial is listed in the EU Clinical Trials Register and updated daily.

Eisenstadt at a glance
861
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

861 trials in Eisenstadt

Open in trial search

Study on Imlifidase for Highly Sensitized Patients with End-Stage Chronic Kidney Disease Awaiting Transplant

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Imlifidase
  • Sponsor:Hansa Biopharma AB

Cardiac amyloidosis

Not recruiting

Study on the Effectiveness and Safety of Eplontersen for Patients with Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Eplontersen
  • Sponsor:Ionis Pharmaceuticals Inc.

Study on BI 1015550 for Improving Lung Function in Patients with Progressive Fibrosing Interstitial Lung Diseases

Investigational
Countries:AustriaAustria
  • Participants:65+ years
  • Substances:Nerandomilast
  • Sponsor:Boehringer Ingelheim Espana S.A.

Hereditary angioedema

Not recruiting

Study on the Safety and Effects of Berotralstat for Children Aged 2 to 12 with Hereditary Angioedema (HAE)

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:0–17 years
  • Substances:Berotralstat
  • Sponsor:Biocryst Pharmaceuticals Inc.

Prostate cancer

Not recruiting

Study of Apalutamide for Patients with High-Risk Prostate Cancer After Prostate Removal

InvestigationalNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Apalutamide
  • Sponsor:Universitaet Muenster

Study on the Effectiveness of Asciminib and Imatinib for Patients with Chronic Myelogenous Leukemia Not Responding to Imatinib

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Imatinib
  • Sponsor:Novartis Pharma AG

Study of Efgartigimod PH20 SC for Adults with Thyroid Eye Disease

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Efgartigimod Alfa
  • Sponsor:Argenx

Long-term Study of Sotatercept for Adults with Pulmonary Arterial Hypertension (PAH)

InvestigationalNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Sotatercept
  • Sponsor:Acceleron Pharma Inc.

Study on the Effects of Obexelimab for Patients with Relapsing Multiple Sclerosis

Investigational
Countries:AustriaAustria
  • Participants:18–64 years
  • Substances:Obexelimab
  • Sponsor:Zenas Biopharma (USA) LLC

Malignant melanoma

Not recruiting

Study on Fianlimab and Cemiplimab for Adults with Resectable Stage III and IV Melanoma

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Cemiplimab
  • Sponsor:Regeneron Pharmaceuticals Inc.

EGFR gene mutation+1

Not recruiting

Study on the Effectiveness and Safety of BAY 2927088 Compared to Standard Treatment in Patients with Advanced Non-Small Cell Lung Cancer with HER2 Mutations

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Bayer AG

Study on the Effect of Extending Imatinib Treatment from Three to Five Years for Patients with High-Risk Gastrointestinal Stromal Tumor (GIST)

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Imatinib
  • Sponsor:Region Skane

Other cities in Austria

The busiest research cities in the country

All 48 cities in Austria

Clinical research in Eisenstadt

What the registry says about research in the country

01 Cardiovascular Research

Innovative clinical research focusing on heart failure and pulmonary hypertension, specifically addressing conditions related to left heart disease. These trials aim to evaluate new therapeutic approaches for patients with complex cardiovascular conditions.

  • Heart Failure Management
  • Pulmonary Vascular Disease
  • Left Heart Disease Complications

The research examines treatment effectiveness in patients with WHO Group 2 pulmonary hypertension, exploring potential improvements in pulmonary vascular resistance over a 24-week period.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.